Buy Crypto Markets Spot FuturesZEC Earn Event Centre Rewards Hub

UroGen Pharma Ltd. (URGN)

NASDAQ

$43.77

$-0.03

(-0.08%)

Pre-Market

UroGen Pharma Ltd. (URGN) Live Price Chart

Last updated: ⁦2026-09-09 10:37:40⁩. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.

Summary

UroGen Pharma Ltd. (URGN) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $43.77, with a market capitalisation of $2.16B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $15.86 to $50.81. This page covers its latest market performance, valuation, price trends and company information.

Key Market Data

Market Cap	$2.16B
Open	$43.80
Day's High	$69.57
Day's Low	$3.42
Previous Close	$43.82
Volume	1.10K
Average Volume	816.88K
P/E Ratio	--
52-Week High	$50.81
52-Week Low	$15.86
Dividend Yield	--
Earnings Date	--

UroGen Pharma Ltd. (URGN) Pre-Market Stock Price

UroGen Pharma Ltd. (URGN) is trading at $43.77 in pre-market trading as of 2026-09-09 09:55:00, down 0.11% ($0.05) from the previous close of $43.82

Pre-market trading shows how investors are pricing URGN before the regular session opens. The current pre-market price is near the previous close, indicating cautious early trading sentiment.

UroGen Pharma Ltd. (URGN) 7-Day Stock Price Change

Over the past seven days, UroGen Pharma Ltd. (URGN) moved from $43.62 to $43.77, representing a gain of 0.34% ($0.15).

The stock traded between $42.00 and $45.88 during the period. The latest price is near the middle of the 7-day range, indicating range-bound.

The average daily volume was 681.63 thousand shares, down versus the previous seven-day period, indicating lower trading activity.

URGN 52-Week Price Position

Position in Range: 79.8%

52W Low$15.86

52W High$50.81

URGN is currently trading at $43.77, placing it 79.8% of the way from its 52-week low of $15.86 to its 52-week high of $50.81. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.

What is UroGen Pharma Ltd. (URGN)?

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.

UroGen Pharma Ltd. Information

Industry	PHARMACEUTICAL PREPARATIONS
Employees	291
Exchange	NASDAQ
Company Website	https://www.urogen.com

How to Buy UroGen Pharma Ltd. (URGN) Stock on MEXC

Eligible investors can buy real shares of UroGen Pharma Ltd. (URGN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.

Step 1: Open and Verify Your RealStocks Account

Log in to the MEXC App, go to Trade → RealStocks, and select Open Account. Complete the required account-opening and identity verification process with MEXC's partner licenced broker.

Step 2: Transfer USDT to Your RealStocks Account

Go to Wallets → RealStocks and transfer USDT from your Spot Account to your RealStocks Account. RealStocks are quoted in USD, while account funding can be completed using USDT.

Step 3: Search for URGN and Place Your Order

Open the RealStocks trading page and search for URGN. Select a market or limit order, enter the price and quantity as required, review the order details, and submit your order. Once filled, the corresponding real shares will be held in your RealStocks Account.

Frequently Asked Questions (FAQ)

1.What is UroGen Pharma Ltd. (URGN) share price today?

UroGen Pharma Ltd. (URGN) is currently trading at $ 43.77, down 0.11% ($0.05) from the previous close of $ 43.82. Intraday prices update in real time during regular trading hours.

2.Is URGN stock going up or down today?

As of 2026-09-09 09:55:00, URGN is trading at $ 43.77, down 0.11% ($0.05) from its previous close of $ 43.82. The stock has traded between $ 3.42 and $ 69.57 during today’s regular session. Past price movements do not guarantee future results.

3.What is URGN pre-market price?

As of 2026-09-09 09:55:00, URGN is trading at $ 43.77 in pre-market trading, down 0.11% ($0.05) from the previous close of $ 43.82. Pre-market prices reflect trading activity before the regular session opens and may experience lower liquidity and higher volatility.

4.What is URGN after-hours price?

As of 2026-09-09 09:55:00, URGN is trading at $ 43.80 in after-hours trading, down 0.03% ($0.02) from the regular-session close of $ 43.82. After-hours prices may differ from the regular session's opening price due to lower liquidity and wider bid-ask spreads.

5.Is URGN stock trading now?

URGN trades on the NASDAQ exchange during regular hours, Monday through Friday, 9:30 AM to 4:00 PM ET, excluding public holidays. Pre-market and after-hours trading are also available through select brokers outside these hours.

6.Where does URGN sit relative to its 52-week high and low?

Over the past 52 weeks, URGN has traded between a low of $ 15.86 and a high of $ 50.81. At $ 43.77, the stock is positioned 79.8% of the way from its 52-week low to its 52-week high, providing context for its current price within the one-year trading range.

7.What sector is UroGen Pharma Ltd. in?

UroGen Pharma Ltd. (URGN) operates in the PHARMACEUTICAL PREPARATIONS sector. Sector classification helps investors compare it with companies exposed to similar market trends and competitive conditions.

8.What is UroGen Pharma Ltd.'s market capitalisation and where is it listed?

UroGen Pharma Ltd. is listed on the NASDAQ exchange with a market capitalisation of $ 2.16B. Market cap reflects the total market value of all outstanding shares and is commonly used to classify stocks by size.

9.How is URGN valued in terms of P/E ratio and EPS?

URGN trades at a P/E ratio of --, based on trailing-twelve-month EPS of $ -2.00. P/E ratio compares the stock price to earnings per share and is a common starting point for assessing valuation relative to peers.

10.Does UroGen Pharma Ltd. pay a dividend?

UroGen Pharma Ltd. pays an indicated annual cash dividend of $ 0.00 per share, with a current dividend yield of 0.00% based on the latest share price. Dividend policies are subject to change at the board's discretion.